Q4 saw a strong rebound within bionics sales
Solid Q4 on the top line, driven by strong performance within the prosthetics subsegment, bionics, which accounted for 25% of prosthetic component sales vs. 23% in Q4'21. The increase was mainly driven by the power knee sales. However, the margins in Q4 did not reach company-collected consensus expectations, with the EBITDA margin reaching 18% (cons. 20%), indicating a slower-than-expected margin uptake, as the company still works to mitigate the increased cost base, with price increases.
Aktuellt
SENASTE
